Bull
$13.97
Scenario price
$23.540
+1.033 (+4.39%)At close
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.
KeyBanc
$30
2026-08-06
KeyBanc
2026-08-06
Price Target
$30
Citi
$34
2026-08-06
Citi
2026-08-06
Price Target
$34
Morgan Stanley
$26
2026-07-22
Morgan Stanley
2026-07-22
Price Target
$26
TD Cowen
$32
2026-06-18
TD Cowen
2026-06-18
Price Target
$32
Morgan Stanley
$23
2026-05-15
Morgan Stanley
2026-05-15
Price Target
$23
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Elanco Animal Health Addresses Year-Round Pet Health Needs

Elanco's Pet Health Business Accelerates Growth Amid Seasonal Changes

Elanco to Announce Q3 2026 Financial Results on November 6

Elanco to Announce Q3 2026 Financial Results on November 6

Elanco Executive Boosts Shareholding, Signaling Confidence
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.
11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.